The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury
Abstract
Drug-induced liver injury (DILI), although rare, is a frequent cause of adverse drug reactions resulting in warnings and withdrawals of numerous medications. Despite the research community’s best efforts, current testing strategies aimed at identifying hepatotoxic drugs prior to human trials are not sufficiently powered to predict the complex mechanisms leading to DILI. In our previous studies, we demonstrated lipophilicity and dose to be associated with increased DILI risk and, and in our latest work, we factored reactive metabolites into the algorithm to predict DILI. Given the inconsistency in determining the potential for drugs to cause DILI, the present study comprehensively assesses the relationship between DILI risk and lipophilicity and the extent of metabolism using a large published dataset of 1036 Food and Drug Administration (FDA)-approved drugs by considering five independent DILI annotations. We found that lipophilicity and the extent of metabolism alone were associated with increased risk for DILI. Moreover, when analyzed in combination with high daily dose (≥100 mg), lipophilicity was statistically significantly associated with the risk of DILI across all datasets (p < 0.05). Similarly, the combination of extensive hepatic metabolism (≥50%) and high daily dose (≥100 mg) was also strongly associated with an increased risk of DILI among all datasets analyzed (p < 0.05). Our results suggest that both lipophilicity and the extent of hepatic metabolism can be considered important risk factors for DILI in humans, and that this relationship to DILI risk is much stronger when considered in combination with dose. The proposed paradigm allows the convergence of different published annotations to a more uniform assessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drugs with high lipophilicity and extensive metabolism in the liver (> 50%) are associated with an increased hepatotoxic potential, especially in combination with a high daily dose (> 100 mg daily).38,39”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
Chen, M., Suzuki, A., Thakkar, S., Yu, K., Hu, C., & Tong, W. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.015 · Cited by 398
Self-citationRisk Factors for Idiosyncratic Drug-Induced Liver Injury
Chalasani, N., & Björnsson, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.001 · Cited by 347
Research works printed but not linked: 30
- Amacher, 2012, The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury, Expert Opin. Drug Metab. Toxicol., 8, 335, 10.1517/17425255.2012.658041 · DOI
- Fontana, 2014, Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives, Gastroenterology, 146, 914, 10.1053/j.gastro.2013.12.032 · DOI · Paper page
- Chen, 2015, Drug-induced liver injury: Interactions between drug properties and host factors, J. Hepatol., 63, 503, 10.1016/j.jhep.2015.04.016 · DOI · Paper page
- Daly, 2009, HLA-b* 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat. Genet., 41, 816, 10.1038/ng.379 · DOI · Paper page
- Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001 · DOI · Paper page
- Monshi, 2013, Human leukocyte antigen (HLA)-B* 57: 01-Restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury, Hepatology, 57, 727, 10.1002/hep.26077 · DOI · Paper page
- Donaldson, 2010, Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury, J. Hepatol., 53, 1049, 10.1016/j.jhep.2010.05.033 · DOI
- Spraggs, 2011, HLA-DQA1* 02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer, J. Clin. Oncol., 29, 667, 10.1200/JCO.2010.31.3197 · DOI · Paper page
- Leise, M.D., Poterucha, J.J., and Talwalkar, J.A. (2014). Drug-induced liver injury. Mayo Clinic Proceedings, Elsevier. · DOI
- Lauschke, V.M., and Ingelman-Sundberg, M. (2016). The importance of patient-specific factors for hepatic drug response and toxicity. Int. J. Mol. Sci., 17. · DOI
- Borlak, 2013, Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury, Genome Med., 5, 86, 10.1186/gm493 · DOI
- Lammert, 2008, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: Search for signals, Hepatology, 47, 2003, 10.1002/hep.22272 · DOI · Paper page
- Lucena, 2009, Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and sex, Hepatology, 49, 2001, 10.1002/hep.22895 · DOI · Paper page
- Lammert, 2010, Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events, Hepatology, 51, 615, 10.1002/hep.23317 · DOI · Paper page
- Chen, 2013, High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury, Hepatology, 58, 388, 10.1002/hep.26208 · DOI · Paper page
- Chen, H., and Boutros, P.C. (2011). Venndiagram: A package for the generation of highly-customizable Venn and Euler diagrams in r. BMC Bioinform., 12. · DOI · Paper page
- Greene, 2010, Developing structure—Activity relationships for the prediction of hepatotoxicity, Chem. Res. Toxicol., 23, 1215, 10.1021/tx1000865 · DOI · Paper page
- Zhu, 2014, Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data, Toxicology, 321, 62, 10.1016/j.tox.2014.03.009 · DOI
- Sakatis, 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds, Chem. Res. Toxicol., 25, 2067, 10.1021/tx300075j · DOI
- Xu, 2008, Cellular imaging predictions of clinical drug-induced liver injury, Toxicol. Sci., 105, 97, 10.1093/toxsci/kfn109 · DOI · Paper page
- Kaplowitz, 2013, Avoiding idiosyncratic DILI: Two is better than one, Hepatology, 58, 15, 10.1002/hep.26295 · DOI
- Danan, 2015, RUCAM in drug and herb induced liver injury: The update, Int. J. Mol. Sci., 17, 14, 10.3390/ijms17010014 · DOI · Paper page
- Lewis, 2014, Causality assessment: Which is best—Expert opinion or rucam?, Clin. Liver Dis., 4, 4, 10.1002/cld.365 · DOI · Paper page
- Lucena, 2008, Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury, Aliment. Pharmacol. Ther., 27, 780, 10.1111/j.1365-2036.2008.03655.x · DOI · Paper page
- Björnsson, E.S. (2016). Hepatotoxicity by drugs: The most common implicated agents. Int. J. Mol. Sci., 17. · DOI · Paper page
- Teschke, 2014, Drug induced liver injury: Accuracy of diagnosis in published reports, Ann. Hepatol., 13, 248, 10.1016/S1665-2681(19)30888-9 · DOI
- Weng, 2015, A comprehensive study of the association between drug hepatotoxicity and daily dose, liver metabolism, and lipophilicity using 975 oral medications, Oncotarget, 6, 17031, 10.18632/oncotarget.4400 · DOI
- Ortega-Alonso, A., Stephens, C., Lucena, M.I., and Andrade, R.J. (2016). Case characterization, clinical features and risk factors in drug-induced liver injury. Int. J. Mol. Sci., 17. · DOI
- Corsini, 2013, Drug-induced liver injury: The role of drug metabolism and transport, J. Clin. Pharmacol., 53, 463, 10.1002/jcph.23 · DOI · Paper page
- Suzuki, 2010, Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in vigibase™, Drug Saf., 33, 503, 10.2165/11535340-000000000-00000 · DOI · Paper page
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Drug-induced liver injury: a comprehensive review
Hosack, T., Damry, D., & Biswas, S. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231163410 · Cited by 214
Thakkar, S., Li, T., Liu, Z., Wu, L., Roberts, R., & Tong, W. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.022 · Cited by 140
Self-citationDrug-induced liver injury: Highlights of the recent literature
Real, M., Barnhill, M. S., Higley, C., Rosenberg, J., & Lewis, J. H. (2019) · Drug Safety · doi:10.1007/s40264-018-0743-2 · Cited by 103
Metadata
- Authors
- McEuen, K., Borlak, J., Tong, W., & Chen, M.
- Affiliations
- Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA
- Center of Pharmacology and Toxicology, Hannover Medical School, Hannover 30625, Germany
- ORCID
- Borlak, Jürgen
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-06-22
- Volume
- 18
- Issue
- 7
- Pages
- 1335
- ISSN
- 1422-0067
- Cited by
- 62
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury. https://app.cochat.ai/papers/10.3390/ijms18071335
- The paper
- McEuen, K., Borlak, J., Tong, W., & Chen, M. (2017). Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms18071335
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.